| Project/Area Number |
24390032
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Environmental pharmacy
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
MISUMI Shogo 熊本大学, 生命科学研究部, 教授 (40264311)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKAMUNE Nobutoki 熊本大学, イノベーション推進機構, 准教授 (60322749)
SHOJI Shozo 熊本大学, 生命科学研究部, 名誉教授 (60040317)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2014: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2013: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2012: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Keywords | HIV-1 / 宿主因子 / ウイルス複製 / 変異 / 根治療法 / 宿主タンパク質 / 翻訳後修飾 / 治療標的 / HIV / ERK2 / ウイルス / 環境 / 抗ウイルス剤 / 薬剤耐性克服 |
|---|
| Outline of Final Research Achievements |
Current drugs against HIV-1 inhibit the function of viral enzymes, namely, RT, integrase, and protease. While these are especially proving useful in combination therapy, drug resistance could still be generated. Therefore, future directions towards a more effective therapy for HIV-1 infection will rely on the development of novel therapeutic strategies rather than conventional strategies, which target only viral proteins. HIV-1 exploits multiple host proteins during infection, suggesting that the possibility of interrupting virus-host interactions may be an important pathway for the development of antiviral therapies. In concept, this type of antiviral agent developed through this pathway could minimize the generation of drug-resistant mutants because the virus must maintain the ability to interact with the relatively immutable host proteins. Thus, the interaction between the host and viral proteins may offer some potential applications for therapies against HIV-1.
|
